Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meloxicam + pridinol is a fixed-dose combination of two pharmaceutical agents used for the treatment of musculoskeletal pain and associated muscle spasms. Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins responsible for pain, inflammation, and fever. Pridinol is a centrally acting skeletal muscle relaxant that alleviates muscle spasms by modulating neural transmission in the central nervous system. The combination provides synergistic effects—meloxicam addresses inflammation and nociceptive pain while pridinol reduces muscle spasm—resulting in superior analgesic efficacy compared to either agent alone. Clinical studies have demonstrated significant improvements in pain scores (VAS and WOMAC) with this combination in patients with musculoskeletal disorders[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meloxicam + pridinol.